BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28787092)

  • 1. New Coumarin Derivatives as Anti-Breast and Anti-Cervical Cancer Agents Targeting VEGFR-2 and p38α MAPK.
    Batran RZ; Dawood DH; El-Seginy SA; Ali MM; Maher TJ; Gugnani KS; Rondon-Ortiz AN
    Arch Pharm (Weinheim); 2017 Sep; 350(9):. PubMed ID: 28787092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
    Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
    Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
    Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
    Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
    Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and molecular docking studies of new furochromone derivatives as p38α MAPK inhibitors targeting human breast cancer MCF-7 cells.
    Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
    Bioorg Med Chem; 2017 Apr; 25(8):2423-2436. PubMed ID: 28291685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors.
    El-Adl K; Abdel-Rahman AA; Omar AM; Alswah M; Saleh NM
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100237. PubMed ID: 34862655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
    El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
    Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZnO Nanoparticles Catalyst in the Synthesis of Bioactive Fused Pyrimidines as Anti-breast Cancer Agents Targeting VEGFR-2.
    Dawood DH; Abbas EMH; Farghaly TA; Ali MM; Ibrahim MF
    Med Chem; 2019; 15(3):277-286. PubMed ID: 30207239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of novel building blocks of benzosuberone bearing coumarin moieties and their evaluation as potential anticancer agents.
    Yadagiri B; Holagunda UD; Bantu R; Nagarapu L; Kumar CG; Pombala S; Sridhar B
    Eur J Med Chem; 2014 May; 79():260-5. PubMed ID: 24742385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
    Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
    Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship studies of 4-methylcoumarin derivatives as anticancer agents.
    Miri R; Nejati M; Saso L; Khakdan F; Parshad B; Mathur D; Parmar VS; Bracke ME; Prasad AK; Sharma SK; Firuzi O
    Pharm Biol; 2016; 54(1):105-10. PubMed ID: 26017566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme.
    El-Adl K; El-Helby AA; Sakr H; Eissa IH; El-Hddad SSA; M I A Shoman F
    Bioorg Chem; 2020 Sep; 102():104059. PubMed ID: 32653608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
    Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridine-Ureas as Potential Anticancer Agents: Synthesis and In Vitro Biological Evaluation.
    El-Naggar M; Almahli H; Ibrahim HS; Eldehna WM; Abdel-Aziz HA
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29914120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents.
    Ragab FA; Eissa AAM; Fahim SH; Salem MA; Gamal MA; Nissan YM
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100029. PubMed ID: 33872414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis and Preliminary Biological Evaluation of Benzylsulfone Coumarin Derivatives as Anti-Cancer Agents.
    Wang T; Peng T; Wen X; Wang G; Sun Y; Liu S; Zhang S; Wang L
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31703373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
    Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.